Pipeline

We have built a leading translational platform to rapidly develop our endobody vaccine pipeline.

The emerging science reveals that similar to heart disease, neurodegenerative diseases start years before symptoms occur and involve a combination of factors. Our pipeline allows us to target common and orphan neurodegenerative diseases early in the disease progression and to manage multiple proteins in combination so as to ultimately lead to more effective treatment.

We are able to leverage our platform technologies to expand our portfolio, which includes three areas of interest within neurological disorders: neurodegenerative proteinopathies, neuroinflammation and regeneration/repair.

Product Candidate (Target)
Indications
Preclinical
IND-Enabling
Phase I
Phase II
Phase III
Proteinopathies
UB-311 (Aβ)
UB-312 (Alpha-Synuclein)
Tau
Neuroinflammation
Regeneration/Repair
Alzheimer's
Parkinson's, MSA
Alzheimer's, CTE

Many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, CTE and frontotemporal dementia, are proteinopathies that are associated with the aggregation and accumulation of misfolded proteins. Different strains of various brain proteins such as beta-amyloid, alpha-synuclein and tau are co-present and underlie these diseases. We are targeting unique epitopes exposed on specific proteinopathy strains to generate endobodies that catalyze their removal for disease treatment and prevention.

UB-311

Our lead vaccine UB-311 is an anti-amyloid endobody vaccine for Alzheimer’s Disease currently in Phase II trials. UB-311 is fully synthetic and employs the UBITh platform technologies to target aggregated forms of beta-amyloid. UB-311 has successfully completed Phase I, demonstrating safety and tolerability, and is currently in Phase II trials. Preliminary data showed efficacy as measured in improvement or stabilization in all three cognitive tests conducted in the target sub-population.

Several inflammatory mechanisms impact nervous system cells to generate pain, autoimmune disease and other behavioral syndromes in both acute and chronic disease settings. We are developing a novel pipeline of endobody vaccines to clamp excessive elevations of specific neuropeptides and cytokines in order to treat migraine and several neuroinflammatory indications.

Neuromuscular diseases impair the functioning of muscles due to problems with the nerves and muscles in the body and include Amyotrophic lateral sclerosis (ALS). We are targeting several signaling proteins that govern tissue differentiation and growth and applying our endobody technologies to repair and regenerate injured and diseased tissues associated with these diseases.